47 / 62
CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
OS – Non-Randomized Cohort
Events/number
at risk
Median OS,
months (95%
CI)
Minimum
follow-up,
a
months
Nivolumab
82/98
4.1 (3.0, 6.8)
19.6
Nivolumab + Ipilimumab
47/61
7.8 (3.6, 14.2)
20.2
1-yr OS = 40%
1-yr OS = 27%
2-yr OS = 14%
Time (months)
OS (%)
100
90
80
70
60
50
40
30
10
0
20
Nivolumab
Number of patients at risk
4
6
7
7
12
17
21
26
35
39
56
98
1
3
7
14
16
19
21
24
28
33
43
61
Nivolumab + Ipilimumab
33
0
30
27
24
21
18
15
12
9
6
3
36
39
0
4
0
1
2-yr OS = 26%
OS = overall survival;
a
Between first dose and database lock; follow-up shorter for patients who died prior to database lock
Ensayos con Combinaciones de Inmunoterapia
Pacientes Pretratados